Business
Palvella Therapeutics Strengthens Leadership Team with Appointment of Veteran Medical Affairs Leader Vimal Patel, PharmD, as Senior Vice President of Medical Affairs
Seasoned dermatology and immunology executive brings more than 25 years of experience advancing and launching innovative therapies, including OPZELURA®, povorcitinib, ILUMYA®, ODOMZO®, REMICADE®, and STELARA® Dr. Patel to lead Palvella’s Medical Affairs organization, advancing scientific engagement, KOL collaboration, disease state awareness, and medical education for the Company’s QTORIN™ programs targeting serious, rare skin diseases, including microcystic lymphatic malformations and cutaneous
About this update from Palvella Therapeutics, Inc.
[{"type":"image","alt":"Palvella Therapeutics Inc.","displaySize":"","headline":null,"caption":"Palvella Therapeutics Inc.","className":"","disableSlideshowImg":false,"size":{"original":{"width":300,"height":300,"url":"https://media.zenfs.com/en/globenewswire.com/4b273ae029a5e8cb06a3771e7b41e04d"},"resized":{"url":"https://s.yimg.com/ny/api/res/1.2/IZ4VZ0Qdm50kE5TTbiIBBg--/YXBwaWQ9aGlnaGxhbmRlcjt3PTQyMDtoPTQyMDtjZj13ZWJw/https://media.zenfs.com/en/globenewswire.com/4b273ae029a5e8cb06a3771e7b41e04d","width":300,"height":300}},"lazy":false},{"type":"text","content":"Seasoned dermatology and immunology executive brings more than 25 years of experience advancing and launching innovative therapies, including OPZELURA®, povorcitinib, ILUMYA®, ODOMZO®, REMICADE®, and STELARA®","length":208,"tagName":"p"},{"type":"text","content":"Dr. Patel to lead Palvella’s Medical Affairs organization, advancing scientific engagement, KOL collaboration, disease state awareness, and medical education for the Company’s QTORIN™ programs targeting serious, rare skin diseases, including microcystic lymphatic malformations and cutaneous venous malformations","length":312,"tagName":"p"},{"type":"text","content":"WAYNE, Pa., Jan. 07, 2026 (GLOBE NEWSWIRE) -- (Nasdaq: PVLA) Palvella Therapeutics, Inc. (Palvella or “the Company”), a clinical-stage biopharmaceutical company focused on developing and commercializing novel therapies to treat patients suffering from serious, rare skin diseases for which there are no U.S. Food and Drug Administration (FDA)-approved therapies, today announced the appointment of Vimal Patel, PharmD, as Senior Vice President of Medical Affairs. Dr. Patel brings more than 25 years of medical affairs leadership experience across dermatology and immunology with deep experience supporting late-stage development, commercial launches, and product lifecycle management.","length":685,"tagName":"p"},{"type":"text","content":"“Vimal brings decades of medical affairs leadership experience, deep dermatology expertise, and a strong track record advancing innovative therapies to patients,” said Wes Kaupinen, Founder and CEO of Palvella. “He brings the energy and leadership needed to ensure our QTORIN™ programs remain guided by rigorous science and thoughtful medical strategy as we advance targeted therapies for serious, rare skin diseases including microcystic lymphatic malf...